Reminyl Safety Signal Reported In Two Cognitive Impairment Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and foreign health authorities are investigating mortality rates from two galantamine studies in the treatment of mild cognitive impairment, Johnson & Johnson says. The studies did not demonstrate Reminyl efficacy in the indication.
You may also be interested in...
J&J's Reminyl Adds Mortality Precaution For Mild Cognitive Impairment
The Precautions section of labeling cites two Reminyl studies in patients with mild cognitive impairment in which the treatment-group mortality rate exceeded that of the placebo arm. J&J issues a "Dear Health Care Professional" letter alerting prescribers to the revised labeling.
J&J's Reminyl Adds Mortality Precaution For Mild Cognitive Impairment
The Precautions section of labeling cites two Reminyl studies in patients with mild cognitive impairment in which the treatment-group mortality rate exceeded that of the placebo arm. J&J issues a "Dear Health Care Professional" letter alerting prescribers to the revised labeling.
AstraZeneca Does Not Expect Crestor Labeling Change Following Fatality
The company says that a fatality potentially caused by rhabdomyolysis appeared in spontaneous adverse event reporting for the cholesterol-lowering drug. AstraZeneca maintains that the evidence concerning the cause of death is more consistent with neuroleptic malignant syndrome.